Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2003-09-26
2009-06-16
Rawlings, Stephen L (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210, C436S501000, C530S328000
Reexamination Certificate
active
07547517
ABSTRACT:
This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, β2microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.
REFERENCES:
patent: 6475783 (2002-11-01), Lucas et al.
Germeau (2005, The J. of Exp. Med. 201(2):241-248).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Drexler et al (Leukemia and Lumphoma, 1993, 9:1-25).
Zellner et al (Clin. Can. Res., 1998, 4:1797-17802).
Lucas et al. (2000, Int. J. Cancer 87:55-60).
Gure et al. (2000, Int. J. Cancer 85:726-732).
Brennan et al (Journal of Autoimmunity, 1989, vol. 2 suppl., pp. 177-186).
Zimmer (Cell Motility and the Cytoskeleton, 1991, vol. 20, pp. 325-337).
Eriksson et al. (Diabetologia, 1992, vol. 35, pp. 143-147).
George et al. (2005, Trends in Immunology 26(12):653-659).
Smith RT, 1994, Clin Immunol, 41(4): 841-849.
Boon (Adv Can Res, 1992, 58:177-210).
Kirkin et al, (1998, APMIS 106:665-679).
Chaux et al. (1998, Int. Int J Cancer 77: 538-542).
White et al. (Ann. Rev. Med., 2001, 52:125-145).
Ezzell (J. NIH Res, 1995, 7:46-49).
Spitler (Cancer Biotherapy, 1995, 10:1-3).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Altman et al. (Science. Oct. 4, 1996; 274: 94-96).
Ma et al. (Int. J. Cancer. 2004; 109: 698-702).
Parker et al. (J. Immunol. Dec. 1, 1992; 149 (11): 3580-3587).
Xu et al. (J. Immunol. Methods. 2002; 268: 21-28).
Karanikas et al. (J. Immunol. 2003; 171: 4898-4904).
Dunbar et al. (Current Biol. 1998; 8: 413-416).
Boon-Falleur Thierry
Coulie Pierre
Germeau Catherine
Ma Wenbin
Van Den Eynde Benoit
Fulbright & Jaworski LLP
Ludwig Institute for Cancer Research
Rawlings Stephen L
LandOfFree
MAGE-C2 antigenic peptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MAGE-C2 antigenic peptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MAGE-C2 antigenic peptides and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4065740